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Abstract
Purpose: Telomere shortening is an important event during carcinogenesis. Although studies suggest role of multiple pro-
teins in telomere length regulation, there is dearth of reports in oral cancer which is a leading malignancy in Asian countries 
especially in India. Thus the present study was carried out to study these mechanisms and explore the pathways involved 
in telomere—telomerase regulation and identify possible prognostic markers to understand the biology of oral tumors for 
better treatment approaches.
Methods: Telomere length was determined by Southern Hybridisation method, telomeric repeat binding factor (TRF) 1 and 
2 expression was detected by Western blot method and telomerase activation by telomeric repeat ampliﬁ  cation protocol. 
Statistical analysis was done using SPSS (Version 10) software.
Results: Signiﬁ  cant shortening of telomeres was seen in the tumor tissues as compared to normal tissues. Poor prognosis 
was observed in the patients with higher telomere length in malignant tissue, higher tumor to normal telomere length ratio 
(T/N TRF LR). Expression of TRF-2 but not TRF-1 protein was signiﬁ  cantly higher in the malignant tissues. We also ob-
served telomerase activation in 75 malignant tissues.
Conclusions: Our results reveal signiﬁ  cant clinical usefulness of telomere length, T/N TRF LR and telomerase activation 
in the prognosis of oral cancer patients. TRF-2 overexpression in malignant tissues appears to play an important role in 
telomere length shortening in oral cancer.
Abbreviations: TRF—Terminal restriction fragment; TRF-1—telomeric repeat binding factor-1; TRF-2—telomeric repeat 
binding factor-2; T/N TRF LR—Tumor/ Normal TRF length ratio.
Keywords: Telomere, TRF-1, TRF-2, prognosis, oral cancer.
Introduction
Telomeres are the extreme ends of double stranded eukaryotic chromosomes comprising tandem array 
of TTAGGG repeats and DNA binding proteins. Telomeric sequences vary among different organisms 
but are usually composed of long arrays of guanine rich sequences (Blackburn, 1991). Human telomeres 
vary with age and cell types and in general range from 6 to 12 kb length in the somatic cells. In humans, 
it consists of repeats of TTAGGG with a 3’ end overhang that helps in the formation of D-loop and 
T-loop structures. Telomeres protect the chromosomal ends from degradation by exonucleases; prevent 
recognition as double stranded DNA breaks, end-to-end fusions, and ring chromosome formation. Thus, 
telomeres play a vital role in the regulation of gene expression, functional organization of the chromo-
some and in controlling the replicative life of cells and entry into senescence.
Recently, it is demonstrated that telomere attrition is an early event in the epithelial carcinogenesis 
(Meeker et al. 2004). Different proteins, like telomeric repeat binding factors (TRF-1 and TRF-2), 
bind to the double stranded telomeric DNA and help in regulating telomere length by different 
mechanisms, either as inhibitors of telomerase or activators of telomere degradation. TRF-1 is 
expressed ubiquitously throughout the cell cycle and binds to TTAGGG repeat as a homodimer with 
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great speciﬁ  city. It inhibits telomerase-dependent 
elongation and participates in regulation of the 
mitotic spindle. TRF-1 is regulated by other 
proteins and acts as negative regulator of telomere 
length (telomerase-dependent pathway). On the 
other hand, TRF-2 stabilizes the G-rich strand over-
hang and inhibits telomere-telomere fusions. TRF-2-
negative telomeres are recognized as damaged 
DNA. Over expression of TRF-2 in somatic cells 
leads to shortening of telomeres thus acting as a 
negative regulator of telomere length. TRF-2 inhibi-
tion is reported to cause apoptosis and non-homol-
ogous end joining of telomeres. The knowledge 
about proteins that bind to the single stranded and 
double stranded telomeric repeats has increased in 
recent years (Oh et al. 2005; Yamada et al. 2002; 
Fujimoto et al. 2003), however; there are very few 
reports showing the expression status during carci-
nogenesis. Although TRF-1 and TRF-2 expression 
is reported in hemopoeitic cells (Yamada et al. 2000), 
adrenal tumors (Kanauchi et al. 2003), lung tumors 
(Nakanishi et al. 2003) and pancreatic tumors (Yajima 
et al. 2001), there are no reports in oral cancer.
Earlier work from our laboratory suggested 
signiﬁ  cant clinical usefulness of telomere length 
analysis and telomerase activation in head & neck 
tumors (Patel et al. 2002). We have also observed 
that telomerase activation, telomerase reverse tran-
scriptase (hTERT) expression are predictors of poor 
survival in the oral cancer patients (Unpublished 
data). Considering these, the present study was 
carried out to understand the mechanisms involved 
in the regulation of telomere length in oral cancer, 
a leading malignancy in India. The study was 
designed to determine the telomere length changes, 
telomerase activation and expression of TRF-1 and 
TRF-2 in oral tumors and to evaluate their clinical 
signiﬁ  cance. Tumor to Normal peak TRF Length 
Ratio (T/N TRF LR) was also calculated to establish 
its clinical signiﬁ  cance in oral cancer.
Materials and Methods
Patients and samples
Hundred untreated oral cancer patients were enrolled 
from the Out Patients department of the Gujarat 
Cancer & Research Institute. The diagnosis was 
established by clinical, histopathological and radio-
logical investigations. Major site of cancer was 
buccal mucosa (n = 36) and tongue (n = 28) and 
others including alveolus, GB sulcus etc. Mean age 
of the patients was 45 years (Age range: 25–72 
years). Tumor staging was done by TNM classiﬁ  ca-
tion of tumors (AJCC, 1997) which is based on the 
tumor size, lymph node involvement and metastasis 
of the tumor. Histopathologically, the tumors repre-
sented squamous cell carcinoma. 80% cases were 
from stage advanced disease (III and IV) and lymph 
node metastasis was evident in 44% oral cancer 
patients. Tissues specimens from the patients were 
collected at the time of surgery. Tumor tissue and 
adjacent normal tissues were selected by a patholo-
gist and later conﬁ  rmed by the histopathological 
examination. Adjacent normal tissues were taken 
from tissue 1 cm or more away away from the tumor 
margins whereever possible and were deﬁ  ned as 
pathologically normal and were used to compare 
with the tumor tissues.
Telomere length by Southern 
Hybridization method
Telomere length changes in the tissues were deter-
mined by Southern hybridization method (Harley 
et al. 1990).
 DNA was extracted from the tissues 
using standard DNA extraction protocols and 
digested using Hinf1 enzyme. Digested DNA 
samples were run on 0.7% agarose gels, transferred 
using capillary transfer method and the membranes 
were hybridized with Digoxigenin (DIG) labeled 
telomeric probe (TTAGGG)n. Signals were detected 
using DIG Chemiluminescence detection method 
and images were captured using Gel documentation 
system, (BioRad, USA). Telomere length was 
measured as peak Terminal Restriction Fragment 
length (TRF), represented in kilo base pairs (kbp), 
which corresponds to the highest peak obtained in 
densitometric scan (Sashida et al. 2003). To avoid 
discrepancy, the range of peak TRF length observed 
in the tissue and mean values are also provided. The 
Peak TRF length was distributed into two groups, 
above and below median for the survival analysis. 
We also calculated the ratio of tumor to normal TRF 
length (paired tissues) and grouped as above and 
below median values.
Telomerase activation 
by TRAP assay
Telomerase activation was analysed by standard 
Telomeric Repeat Ampliﬁ  cation Protocol (TRAP) 
using commercially available kit (Roche Molecular 
Biochemicals, Germany). Malignant and adjacent 
normal tissues were pulverized using liquid nitrogen, 
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to this 200 µl of ice cold lysis reagent was added 
for cell lysis and incubated on ice for 30 minutes. 
Lysate were centrifuged for 20 minutes at 15,000 
rpm at 2–8°C. The supernatant was collected in a 
fresh tube. Protein concentration was estimated by 
Folin Lowry method (Lowry et al. 1951). BSA was 
used as a standard for the calculation of proteins. 
Aliquots of the supernatant were prepared and stored 
at –80°C, until analyzed. 50 µg protein aliquot was 
used for the telomerase mediated primer elongation 
and later ampliﬁ  ed by PCR and the products were 
run on 15% denaturing PAGE, transferred onto 
nylon membrane detected by Chemiluminescence 
detection kit (Roche Molecular Biochemicals, 
Germany). 293 kidney cells provided with the kits 
were used as telomerase positive control and lysis 
buffer was used for negative control. The samples, 
which showed characteristic six base pair DNA 
ladder, were considered telomerase positive.
Expression of TRF-1 and TRF-2 by 
Western blot method
Tissues were homogenized in phosphate buffer 
saline (pH: 7.4) and centrifuged at 15,000 rpm for 
15 minutes. Supernatant were collected and used 
for determination of protein content by Lowry 
method. Aliquot equivalent to 100 µg protein was 
used for electrophoresis. Transfer of protein to ECL 
membrane was done by Semi Dry transfer method 
Multiphore II Nova Blot Unit (Amersham Biosci-
ences, U.S.A.). Monoclonal antibodies against 
TRF-1 and TRF-2 (Calbiochem, U.S.A.) were used 
at a concentration of 1 µg/ml and secondary anti-
body was diluted 1:1000 in Tris buffered saline. 
Detection was carried out by ECL detection kit 
(Amersham Biosciences, U.S.A.). Scanning and 
quantitation of bands was carried out by Gel Docu-
mentation system (Bio Rad, U.S.A.) and results 
were represented as OD/mm
2.
Statistical analysis
Statistical analysis was carried out using SPSS 
software (Version 10). Comparison of means was 
done by unpaired and paired t-tests. ANOVA and 
multivariate tests were performed to determine the 
association of markers with clinical parameters. 
Kaplan Meier survival curves were plotted to 
determine the effect of peak TRF length, T/N TRF 
LR on the survival of patients. The comparison of 
the survival in the two groups was done by Log 
Rank Statistics. For the statistical analysis p value 
<0.05 was considered signiﬁ  cant.
Results
Peak TRF length in the tissues and 
association with clinical details
In the present study peak TRF length ranged from 
4.1 to 15.6 kbp in the malignant tissues and 3.8 to 
17.6 kbp in the adjacent normal tissues as shown 
in Table 1. Representative pattern for peak TRF 
length in the malignant and adjacent normal tissues 
of patient with carcinoma of buccal mucosa and 
tongue is given in Figure 1. Students t-test 
(unpaired and paired) demonstrated that mean peak 
TRF length in the malignant tissues (8.18 kbp) was 
signiﬁ  cantly shorter (p < 0.001) then the adjacent 
normal tissues (9.97 kbp).
We also observed that increase in peak TRF 
length was associated with progression of disease, 
well differentiated tumors as well as increasing 
tumor size (Table 2). Also peak TRF length in the 
lymph node positive patients was shorter then the 
lymph node negative patients. A decrease in telo-
mere length was observed with increasing age 
which was statistically not signiﬁ  cant. Further, in 
multivariate analysis to determine the association 
of telomere length changes, we found a signiﬁ  cant 
association between tumor differentiation and 
telomere length (p = 0.05) only (Table 3).
Survival analysis
Effect of telomere length on survival of the 
patients was determined by Kaplan Meier survival 
method. For this median peak TRF length for the 
Table 1. Mean Peak TRF length (in kbp) in the tissues.
Tissues (N = 85)  Range of peak TRF length (in kbp)  Mean peak TRF length (in kbp)
Malignant tissues  4.1 to 15.6  8.18
Adjacent normal tissues  3.8 to 17.6  9.97
Student t-test and paired t-test: p value < 0.001
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malignant and adjacent normal tissues were deter-
mined and the patients were grouped into above 
and below median groups. Survival analysis 
revealed that patients having higher peak TRF 
length in the malignant tissues had signiﬁ  cantly 
poor ﬁ  ve-year disease free survival as compared 
to the patients showing peak TRF length less than 
the median (Figure 2A). Thus, it is evident that 
higher telomere length might be indicative of 
increased capability of the cells to undergo addi-
tional number of divisions, hence longer prolif-
erating capacity.
T/N TRF LR in the patients
The ratio of tumor and respective adjacent normal 
TRF length to nullify the telomere length differ-
ences between two groups were determined. The 
ratio ranged from 0.28 to 1.55 in the patients and 
was grouped into above and below median group. 
Although T/N TRF LR was not associated with 
the clinical features of tumor, it showed signiﬁ  -
cant association with the survival of the patients 
(Figure 2B). Patients having higher T/N TRF 
ratios showed signiﬁ  cantly shorter survival of 
21.2 months as compared to the patients having 
Table 2. Association of peak TRF length with the clinico-pathological features of tumors.
  Peak TRF length →(in kbp)  Malignant tissue (N = 85)  Adjacent normal tissue (N = 85)
Age groups
 I  8.18 9.6
 II  7.87 10.11
 III  8.60 10.4
Tumor differentiation
 Well  7.7  10.23
 Moderate  8.35  9.53
 Poor  9.51  10.1
Disease Stage
 Stage  1  6.75  7.34
 Stage  2  7.72  9.27
 Stage  3  10.1  10.01
 Stage  4  8.28  9.35
Nuclear grade
 I  7.47  10.04
 II  8.42  9.32
 III  9.13  10.75
Tumor size
 T1  8.11  8.23
 T2  8.08  9.27
 T3  9.30  10.30
 T4  7.94  10.44
Lymph node status
 Positive  8.0  9.23
 Negative  8.45  10.38
Figure 1. Representative pattern for peak TRF length in tissues.
MW: Represents the DIG labeled DNA molecular weight marker 
(0.5-23.2 kilo base pairs).
Lane 1 & 2: Peak TRF length in adjacent normal and malignant tissue 
specimens from patient with carcinoma of buccal mucosa.
Lane 3 & 4: Peak TRF length in adjacent normal and malignant tis-
sues from patients with carcinoma of tongue.
MW       1        2       3          4
2.0
2.3
4.4
6.6
9.4
23.2
kbp
0.5
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lower ratio who had survival of 42.8 months. The 
present results suggest that higher T/N TRF LR 
in patients may confer growth advantage to the 
tumors by providing longer proliferating 
capabilities.
Expression of TRF-1 and TRF-2 and 
association with clinical parameters
Figure 3 exhibits representative pattern for expres-
sion of telomeric repeat binding proteins carried 
by Western blot method. Expression of TRF-1 
protein was detected in 56.0% malignant and 
20.0% adjacent normal tissues while TRF-2 
expression was seen in 76.0% malignant and 
44.0% of the adjacent normal tissues. When the 
mean expression levels were compared (Table 4), 
TRF-2 protein expression was signiﬁ  cantly higher 
in the malignant tissues (p < 0.001) then the adjacent 
normal tissues.
One-way ANOVA was carried out to determine 
the association of TRF-1 and TRF-2 expression 
with the clinicopathological factors. ANOVA 
analysis revealed inverse relation of TRF-1 expres-
sion with disease stage, tumor differentiation and 
tumor size however no association was observed 
with lymph node metastasis. None of the differ-
ences were statistically signiﬁ  cant in the present 
analysis. In the adjacent normal tissues, TRF-1 
expression was signiﬁ  cantly associated with the 
disease progression i.e. from stage 1 to stage 4. 
Details of ANOVA test are provided in Table 5A. 
Further, in the adjacent normal tissues TRF-1 
protein levels showed signiﬁ  cant association with 
increasing tumor size. This might be suggestive of 
role of TRF-1 expression during the clinical course 
of disease. Expression of TRF-2 protein was 
signiﬁ  cantly associated with the disease stage in 
the adjacent normal tissues. In multivariate 
analysis, we did not observes association between 
TRF-2 expression and clinicopathological features 
like stage, tumor differentiation, nuclear grade, 
tumor size and nodal invasion was observed as 
shown in Table-6.
Telomerase activation in tissues and 
association with telomere length
A characteristic six base DNA ladder in the speci-
mens was considered to be telomerase positive 
(Figure 4). Telomerase activation was observed in 
75% of the tumor tissues and 62.4% of the adjacent 
normal tissues. Further, peak TRF telomere length 
in the telomerase positive and negative tissues was 
compared. Normal tissues in both telomerase posi-
tive and negative tissues showed higher telomere 
length then the tumor tissues (Figure 5).
Correlation of proteins with 
telomere shortening
Spearman’s correlation coefﬁ  cients were computed 
to determine association of proteins with telomere 
length. TRF-1, TRF-2 expression and telomerase 
activation showed a negative association with 
telomere length changes in the tissues (p = 0.30; 
0.79; 0.17 respectively).
Discussion
Telomeres are progressively shortened at each cell 
cycle due to end replication problem faced by the 
eukaryotic cells which ﬁ  nally leads to the growth 
arrest of these cells at a stage termed as senescence. 
However, cells acquire additionally forced prolif-
eration capacity which ﬁ  nally leads to signiﬁ  cant 
telomere shortening (Wright and Shay, 2005). It is 
known that loss of capping function of telomeres 
results in chromosomal end to end fusion and 
Table 3. Multivariate analysis for association of peak TRF length with clinicopathological features of tumors.
  Malignant tissue  Adjacent normal tissue
Parameters F  ‘p’ value  F  ‘p’ value
Age 0.923  0.58  0.893  0.61
Sex 1.949  0.17  1.358  0.25
Differentiation  2.935 0.05 1.906  0.15
Nuclear Grade  2.202  0.13  0.543  0.58
Lymph Node  0.586  0.45  1.499  0.23
Stage 0.019  0.89  0.507  0.48
Habit 0.220  0.88  0.257  0.85
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Figure 2. Survival curves for peak TRF length and T/N TRF LR in oral cancer patients.
2B. Peak TRF length in the adjacent normal tissues 
2C. T/N TRF length ratio in oral cancer patients 
2A. Peak TRF length in malignant tissues 
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formation of ring chromosomes (van Steensel 
et al. 1998). Also, telomeres when not replicated 
are bound by protein complex and protected by 
degradation (Wright and Shay, 2005).
In the present study, the peak TRF length in the 
malignant tissues ranged from 4.1 to 15.6 kbp while 
in the adjacent normal tissues it varied from 3.8 to 
17.6 kbp. We found signiﬁ  cantly shorter peak TRF 
length in the tumor tissue as compared to their 
normal counterparts in paired t-test, which suggests 
that telomere shortening occurs during carcingen-
esis. Other investigators (Lantuejoul et al. 2005; 
Gertler et al. 2004; Plentz et al. 2004; Oh et al. 
2005; Patel et al. 2002) have also reported shorter 
telomere length in the tumor tissues. Recently 
Meeker et al. (2005) also reported that telomere 
length abnormalities are one of the earliest genetic 
alterations during the multi step epithelial 
carcinogenesis.
We observed inverse association between telo-
mere length and lymph node metastasis. Telomere 
length alterations also showed negative association 
with age and tumor differentiation in the adjacent 
normal tissues which was not evident in tumor 
tissues. Similar association has been reported by 
Wu et al. (2003) in multiple myeloma patients. 
Telomere length is signiﬁ  cantly associated with 
advanced disease (Gertler et al. 2004), tumor 
pathology and grade (Plentz et al. 2004).
Survival analysis suggested signiﬁ  cantly shorter 
survival in the patients having longer telomere 
length in the malignant tissues than those with 
shorter telomere length. This may be because the 
  66kD protein 
  N           M           N          M          N         M 
Figure 3. Representative pattern for expression of TRF-1 and TRF-2 in the malignant and adjacent normal tissues.
M = Malignant tissues.
N = Adjacent normal tissues.
A: TRF-1 expression in tissues
B: TRF-2 expression in tissues
Table 4. Mean values of TRF-1 and TRF-2 in the 
tissues.
Tissues(N = 25)  Mean ± S.E.  Signiﬁ  cance
TRF-1
Malignant  1.61 ± 0.52  0.49
NS
Adjacent Normal  1.05 ± 0.62
TRF-2
Malignant  9.54 ± 2.58 
0.005* Adjacent Normal  2.03 ± 0.86
Table 5A. ANOVA table for association of TRF-1 with clinical factors.
  Malignant tissue  Adjacent normal tissue
TRF-1 Factor  F value  ‘p’ value  F value  ‘p’ value
Stage   1.084  0.380  9.900  <0.01
Differentiation 0.936  0.443  1.211  0.333
Nuclear grade  1.530  0.240  2.100  0.147
Tumor size  0.624  0.609  6.900  0.003
Nodal invasion  0.536  0.472  0.348  0.562
  44kD protein 
N MM M N N
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cells need to proliferate continuously for longer 
duration for the survival of tumors. Likewise, it is 
true that cells with longer telomeres will survive 
for more cell divisions and will have longer life 
span, thus conferring poor disease free survival 
among the patients. Earlier similar association was 
reported in head & neck cancer (Patel et al. 2002), 
endometrial tumors (Menon et al. 2003), and 
colorectal carcinoma (Rosenberg et al. 2003). This 
observation was further demonstrated by deter-
mining T/N TRF LR. Higher T/N TRF ratio is 
reported to be signiﬁ  cant indicator of poor survival 
in lung and gastric cancers (Hsu et al. 2004). In 
our study group we found signiﬁ  cant association 
of higher T/N TRF LR with shorter survival of oral 
cancer patients. The T/N TRF LR takes into 
account the differences in the tissue pairs as well 
as the cellular ageing related changes. Thus, telo-
mere length changes measured in terms of T/N 
TRF ratio is a better marker to determine the actual 
signiﬁ  cance of telomere length alterations during 
cancer.
The double-stranded TTAGGG repeats of 
mammals are bound by two related proteins, TRF-1 
and TRF-2 (Chong et al. 1995; Broccoli et al. 
1997). Overexpression of TRF-1 results in telomere 
shortening, whereas mutants that are defective in 
DNA binding give rise to telomere lengthening 
(Smogorzewska et al. 2000). If TRF-2 is removed 
from telomeres in human cell lines the chromo-
some ends are immediately recognized as sites of 
DNA breaks, leading to chromosome end-to-
end fusions, the activation of the p53 and p16/RB 
pathways, and the induction of senescence or 
apoptosis (Smogorzewska and de Lange, 2004). 
The expression levels of both TRF-1 and TRF-2 
were higher in the malignant tissues as compared 
to their normal counterparts. So far, there are no 
studies on the role of TRF-1 and TRF-2 proteins 
in human oral cancer. In human oral cancer cell 
lines, Fujimoto et al. (2003) have shown involve-
ment of TRF-1 up-regulation in normal cell senes-
cence. Earlier studies have presented controversial 
data for these telomeric genes in cancer. Some 
studies suggested that TRF-1 and TRF-2 were 
down-regulated in tumor tissues (Yamada et al. 
2002; Saito et al. 2002; Yamada et al. 2000), 
whereas others showed that TRF-1 or TRF-2 was 
up-regulated (Oh et al. 2005; Nakanishi et al. 2003; 
Ancelin et al. 2002). It is also suggested that in the 
absence of TRF-1, TRF-2 takes over the function 
of stabilizing telomeres along with the telomere 
interacting proteins and thereby block the access 
to telomerase (Smogorzewska and de Lange, 
2004).
Loss of TRF-1 can result in telomere length-
ening and extended life span of cells. Expression 
of TRF-1 is considered to be a homeostatic 
mechanism to control the proliferative potential 
of normal cells and directly acts by inhibiting 
telomerase activity (Smogorzewska et al. 2000). 
Overexpression of TRF-1 is associated with 
Table 6. Multivariate analysis for association with TRF-1 and TRF-2 expression in the tissues.
Parameters  TRF-1 expression  TRF-2 expression
  ‘F’ value   Signiﬁ  cance  ‘F’ value  Signiﬁ  cance
Age 0.701  0.695  0.859  0.618
Nuclear Grade  1.495  0.281  0.290  0.756
Lymph Node  0.841  0.386  0.409  0.541
Stage 0.081  0.923  0.106  0.901
Table 5B. ANOVA table for association of TRF-2 with clinical factors.
  Malignant  Adjacent Normal tissue
TRF-2 Factor  F value  ‘p’ value  F value  ‘p’ value
Stage   0.133  0.939  5.250  0.010
Differentiation 0.098  0.960  0.080  0.770
Nuclear grade  0.088  0.916  0.119  0.885
Tumor size  0.599  0.626  1.659  0.218
Nodal invasion  0.083  0.777  0.326  0.575
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decreased telomere length via inhibition of 
telomerase activity in the cells. One possible 
mechanism to explain the role of TRF-1 in telo-
mere maintenance suggested sequential post-
translational modifications of TRF-1 which 
regulated access of telomerase to telomeres 
(Chang et al. 2003). Normally, TRF-1 is in 
conﬁ  guration that blocks access to telomerase, 
however tankyrase ribosylates TRF-1 and 
removes them from telomeres. TRF-1 complex 
removed from telomeres is then degraded 
by proteosome complex. Telomerase causes 
extension of telomeres. Once the telomeres are 
lengthened, newly synthesized TRF-1 reassemble 
and form a telomerase inaccessible state. The 
constant shuttling of TRF-1 helps in the mainte-
nance of telomere length.
Inverse association of TRF-1 expression with 
disease stage, tumor differentiation and tumor size 
was observed. In the adjacent normal tissues, TRF-1 
expression was signiﬁ  cantly decreased with increase 
in disease stage. This is possibly due to the fact that 
in advanced disease requirement of TRF-1 and 
TRF-2 molecules is reduced, due to shorter telo-
mere length in the tissues. In breast cancer TRF-1 
expression was associated with tumor size (Saito 
et al. 2002). Association of telomeric proteins, 
TRF-1 and TRF-2, appears to be different in 
various malignancies and needs to be clearly 
deﬁ  ned. In oral cancers, our data suggests that 
TRF-2 over expression seems to be an important 
event for telomere length regulation, however 
further studies in oral cancer cells and human 
tissues will enable to asses the potential use of these 
proteins.
Telomerase activation is observed in more than 
80% of cancers but is absent in most of the normal 
somatic cells. Telomerase activation is required to 
prevent further loss of telomeres and maintain 
telomere length. In previous study (Sotillo et al. 
2004) shorter telomere length was observed in the 
patients with detectable telomerase activity 
(p = 0.041), however we did not observe any differ-
ence in telomere length in telomerase positive and 
negative groups. This might be due to certain 
telomerase independent pathways like alternate 
lengthening of telomeres (ALT pathway) which 
exist in the cells (Muntoni and Reddel, 2005). 
Usually ALT positive cells demonstrate longer 
telomeres as compared to ALT negative cells. Thus 
apart from telomerase, several other proteins 
appear to be an important integral requirement for 
the maintenance of telomere length.
The study deciphers important clues regarding 
telomere biology in oral tumors, a malignancy 
less explored with this aspect. Telomere length 
and T/N TRF LR prove to be useful tools to deter-
mine the prognosis of oral cancer patients. Over 
expression of TRF-2 protein in the oral tissues 
suggests loss of capping function that results in 
end to end fusion often observed in cancer cells. 
Thus, it reﬂ  ects that telomere dependent genomic 
alterations caused due to imbalance of proteins 
at the telomeric end play a major role in cancer 
and might help in identifying newer therapeutic 
  1     2       3      4       5      6       7     8 
Figure 4. Telomerase activation in the tissues.
N = Adjacent normal tissue; M = Malignant tissue; +ve = positive 
control; –ve = negative control.
Lane-1 and lane-2 represent telomerase positive control, 293-kidney 
cell lysate and telomerase negative control respectively.
Lane 3, 4 represents telomerase negative adjacent normal tissue and 
telomerase positive malignant tissue of buccal mucosa patient. 
Lane 5, 6 represent telomerase positive adjacent normal and malignant 
tissue from tongue carcinoma patient. 
Lane 7, 8 represents telomerase positive adjacent normal and 
malignant tissues from buccal mucosa patient.
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targets. At the time when telomere and telomerase 
are being considered as a potential drug targets, it 
becomes imperative to identify the role of these 
proteins in both cell culture studies and human 
studies. Further analysis of these proteins is essential 
to strengthen the interesting observations of the 
present work and elucidate the mechanism involved 
in telomere length shortening in oral cancer.
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